We are live on ! Find out more

AtaiBeckley Inc

ATAI

Market cap $2.73B

7.35 USD

+0.06

0.82%

At close Updated Sep 10, 4:00 PM EDT

Pre-market

After hours

7.33

-0.02

0.27%

1 day

0.82%

5 days

0%

1 month

1.38%

3 months

94.44%

6 months

77.54%

Year to date

89.92%

1 year

55.72%

5 years

-55.35%

10 years

-62.21%

About: AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Employees: 99

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 62.5%

Neutral 35.4%

Negative 2.1%

Zacks Investment Research

Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?

AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock?

Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?

Zacks Investment Research

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Jim Cramer Isn't Sure If There's Upside In This Health Care Stock

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he is not sure that there's a lot of upside in AtaiBeckley Inc. (NASDAQ:ATAI).

Jim Cramer Isn't Sure If There's Upside In This Health Care Stock

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AtaiBeckley Inc. (NasdaqGM: ATAI) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of AtaiBeckley will receive $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments u.

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI

Zacks Investment Research

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know

The mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know

The Motley Fool

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

One of Cathie Wood's funds just sold some AtaiBeckley shares. It also bought some Compass Pathways shares.

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly

MONSEY, N.Y., July 28, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of AtaiBeckley, Inc. (Nasdaq: ATAI) (“AtaiBeckley”) to Eli Lilly and Company (“Lilly”), pursuant to which AtaiBeckley shareholders will receive $6.75 per share in cash, plus a contingent value right (“CVR”) worth up to an additional $2.50 per share.

ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly

Zacks Investment Research

How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%

The consensus price target hints at a 33.3% upside potential for AtaiBeckley Inc (ATAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Thursday's announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma's increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health conditions. Several psychedelic substances — LSD, psilocybin (aka magic mushrooms), MDMA, ayahuasca and ibogaine  — are being studied by new drug companies to treat depression, post traumatic stress disorder, anxiety, eating disorders and alcohol and drug addiction.

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AtaiBeckley Inc. (NasdaqGM: ATAI) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of AtaiBeckley will receive $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments u.

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI

See News Rankings

Price charts implemented using Lightweight Charts™